|
Neovacs, a spin-off
from Pierre & Marie Curie University in Paris, is a
biotechnology company focused on an active immunotherapy
technology platform, with applications in autoimmune
diseases and other chronic conditions. It
was founded by Professor Daniel Zagury, MD, PhD, one of the
world’s leading immunologists.
The Company’s
lead program, an immunotherapy targeting certain
inflammatory diseases, is currently in a Phase 1/2 study
in subjects with Crohn’s Disease and a Phase 2 study in rheumatoid arthritis patients who have failed at least one prior TNFα inhibitor. This product
candidate is also the subject of a collaboration with
the diagnostics company BMD, with the objective of
developing the theranostic tools to permit personalized
care. The clinical program has received
substantial public funding support from Oséo
ISI.
Near term milestones for
Neovacs include completion of the Phase 1/2 study, completing enrollment in the Phase 2 study in RA, starting a Phase 2 study in Crohn’s Disease, and the initiation of clinical trials of a second
product, an immunotherapy targeting Lupus disease (H1
2010). The Company’s R&D has also generated a
broad patent
estate.
|